About krystal biotech inc - KRYS
Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
KRYS At a Glance
Krystal Biotech, Inc.
2100 Wharton Street
Pittsburgh, Pennsylvania 15203
| Phone | 1-412-586-5830 | Revenue | 389.13M | |
| Industry | Biotechnology | Net Income | 204.83M | |
| Sector | Health Technology | 2025 Sales Growth | 33.945% | |
| Fiscal Year-end | 12 / 2026 | Employees | 295 | |
| View SEC Filings |
KRYS Valuation
| P/E Current | 37.774 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 36.05 |
| Price to Sales Ratio | 18.976 |
| Price to Book Ratio | 5.901 |
| Price to Cash Flow Ratio | 36.76 |
| Enterprise Value to EBITDA | 39.117 |
| Enterprise Value to Sales | 16.873 |
| Total Debt to Enterprise Value | 0.001 |
KRYS Efficiency
| Revenue/Employee | 1,319,084.746 |
| Income Per Employee | 694,342.373 |
| Receivables Turnover | 3.054 |
| Total Asset Turnover | 0.326 |
KRYS Liquidity
| Current Ratio | 9.953 |
| Quick Ratio | 9.56 |
| Cash Ratio | 8.041 |
KRYS Profitability
| Gross Margin | 92.606 |
| Operating Margin | 41.45 |
| Pretax Margin | 48.691 |
| Net Margin | 52.638 |
| Return on Assets | 17.143 |
| Return on Equity | 18.914 |
| Return on Total Capital | 16.668 |
| Return on Invested Capital | 18.796 |
KRYS Capital Structure
| Total Debt to Total Equity | 0.766 |
| Total Debt to Total Capital | 0.76 |
| Total Debt to Total Assets | 0.70 |
| Long-Term Debt to Equity | 0.621 |
| Long-Term Debt to Total Capital | 0.616 |